Trade Exicure, Inc. - XCUR CFD

Trading Conditions

• Spread: 0.06
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 0.48
• Open: 0.48
• 1-Year Change: -46.07%
• Day's Range: 0.48 - 0.49

Exicure, Inc. Company profile

About Exicure Inc

Exicure, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its spherical nucleic acid (SNA) technology. The Company develops XCUR-FXN, which is a spherical nucleic acid (SNA) -based therapeutic candidate for the treatment of Friedreich’s ataxia (FA). XCUR-FXN through its SNA technology incorporates more than one active oligonucleotides in a single SNA molecule. The Company’s therapeutic candidate cavrotolimod (AST-008) is a toll-like receptor 9 (TLR9) agonist designed for immuno-oncology applications utilizing its SNA technology. AST-008 is in a Phase I b/II clinical trial in patients with advanced solid tumors. TLR9 agonists binds to and activate TLR9.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Exicure Inc revenues decreased from $16.5M to -$2.6M. Net loss increased from $12M to $50.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development expense - Balan increase of 69% to $36.5M (expense), General and administrative expense - Bal increase of 25% to $7.8M (expense).